COO

Analyst Note: The Cooper Companies, Inc. (COO)

Date: 2026-06-13 Current Price: $65.91

1. Structural Readiness

State: Context-Only Conservative Entry: — (Not yet triggered; requires a confirmed breakout above the defined resistance structure) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Pending confirmation) Current Price: $65.91 Extension: — ATR Current: 2.7% (Productive)

Analysis of Setup:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None Named. Assessment: As of 2026-06-13, there is no named secular macro thesis driving this specific trade. This is a tactical, setup-led name. The conviction must be derived entirely from the quality of the structural setup (the forming coil) and the underlying business fundamentals. No external narrative or sector-wide tailwind is being assumed for this analysis; the trade is judged on the company's execution and the technical structure's integrity.

3. Business Overview

Company: The Cooper Companies, Inc. (COO) Industry: Healthcare / Medical Devices Business Model: The company operates as a global medical device firm with two distinct business units: CooperVision and CooperSurgical.

• CooperVision: A global manufacturer of contact lenses. The segment develops, manufactures, and markets a broad range of products including spherical lenses, toric lenses (for astigmatism), multifocal lenses (for presbyopia), and specialized options for myopia management, dry eyes, and eye fatigue.
• *Evidence:* The segment reported solid performance in the quarter ended April 30, 2026, with revenues increasing 8% (4% organically), driven by strength in the Americas and momentum in EMEA (E5).
• *Growth Drivers:* The segment is benefiting from the success of Biofinity and MyDay lenses, with Toric and multifocal categories growing primarily through these products (E12). Market gains in silicone hydrogel contact lenses were the primary driver of net sales growth in the Americas and EMEA (E13).
• *Regulatory Milestones:* As of the reporting period, CooperVision received approval for its MiSight 1 day lens in China (NMPA) and Japan (MHLW), expanding its addressable market in Asia (E10, E18).
• *Guidance:* Management is guiding to full-year organic growth of 3.5% to 4.5% for CooperVision (E1).

• CooperSurgical: A provider of products and services focused on fertility and women's health. The portfolio includes fertility products, medical devices, cryostorage (cord blood/tissue), and contraception.
• *Evidence:* In the three months ended April 30, 2026, office and surgical net sales increased due to higher sales of surgical products. Fertility net sales grew primarily due to increased revenue from consumables and genetic testing (E14).
• *Specific Performance:* The fertility segment performed well, growing 10% organically to $144 million in the reported quarter (E6).
• *Guidance:* Management maintains unchanged guidance for CooperSurgical of 4% to 5% organic growth for the full year (E2).
• *Market Context:* Management cites ongoing trends of delayed childbirth and expanding access to care as fundamental industry drivers (E7).

• Financial Health:
• *Margins:* Consolidated gross margin remained flat at 68% for both the three and six months ended April 30, 2026, compared to the prior year period (E15).
• *Cash Flow:* Management increased its 2026 free cash flow outlook to roughly $650 million, excluding litigation payouts (E3).
• *Global Reach:* The company sells products in over 130 countries and impacts over 50 million lives annually (E16).

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: COO fits the Quality Compounder archetype. The evidence points to a company with a diversified, high-margin business model (68% gross margin) that is executing well across two distinct, secularly relevant verticals (vision correction and fertility/women's health).

• Margin Inflector: The company has maintained a stable 68% gross margin despite inflationary pressures, indicating strong pricing power and operational efficiency.
• Growth Leader: Both segments are delivering double-digit growth in specific sub-categories (Fertility +10% organically) and are guiding to mid-single-digit organic growth for the full year.
• Valuation Context: The financial spine indicates a forward consensus EPS of $4.63 for FY1 and $5.02 for FY2 (E30). This implies a forward P/E ratio of approximately 14.2x based on the current price of $65.91, which is reasonable for a high-quality compounder in the healthcare sector.

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led only).
• Evidence Quality: High. The earnings transcript and SEC filings provide granular data on segment performance, regulatory approvals, and cash flow guidance.
• Setup Readiness: Partial. The setup is "Forming," meaning the structure is in place, but the catalyst (breakout) has not occurred.
• Rerating Potential: Moderate. The combination of FCF growth ($650M), regulatory wins in China/Japan, and stable margins provides a fundamental basis for a multiple expansion *if* the technical breakout occurs.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Fundamental: A significant miss on the guidance for organic growth (currently 3.5-4.5% for Vision, 4-5% for Surgical) or a deterioration in gross margins below the 68% level.
• Litigation: Unexpectedly large litigation payouts that materially impact the $650M FCF guidance.

What Would Strengthen:

• Fundamental: Acceleration in the fertility segment beyond the 10% organic growth seen in the quarter, or faster-than-expected revenue ramp-up from the new MiSight approvals in China and Japan.
• Management: Further upward revisions to the FCF guidance or EPS estimates.

Gaps in Evidence:

• Breakout Level: The specific resistance level that must be breached for a "Confirmed" status is not defined.
• Litigation Details: While litigation payouts are mentioned as a deduction from FCF, the specific nature or magnitude of these liabilities is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management increased 2026 FCF outlook to $650M; Fertility segment grew 10% organically to $144M; MiSight lens approved in China and Japan; Gross margin stable at 68%. Key risks: Technical setup is only "forming" and requires a breakout to confirm; Litigation payouts could reduce FCF; Guidance for organic growth is mid-single-digit, not high growth; ATR of 2.7% is below the historical high-momentum sweet spot. Sizing hint: Position size should be calibrated to the "forming" nature of the setup; smaller initial size until breakout confirmation, with scaling on the move above resistance. Expected path: Management expects continued strength in the back half of the year with fertility growing in the mid-single-digit range; structural implication is that if the breakout fires, the stock will likely test higher levels supported by the $5.02 FY2 EPS consensus. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.